Table 2.

Univariate analysis of markers evaluated for an association with progression in uterine serous carcinomas (USC) patients

Marker	Univariate analysis, unadjusted		Univariate analysis, adjusted for stage†
	HR (95% CI)	P‡	HR (95% CI)	P‡
FBXW7 nuc	0.85 (0.71,1.01)	0.07	0.80 (0.66, 0.97)	0.024
pGSK3β cyt	1.01 (0.74,1.37)	0.96	1.09 (0.75, 1.57)	0.67
Cyclin E nuc	0.96 (0.77,1.19)	0.69	1.05 (0.85, 1.29)	0.64
Aurora A nuc	1.14 (0.82,1.59)	0.44	0.89 (0.65, 1.22)	0.46
Aurora A cyt	1.29 (0.97,1.72)	0.08	1.22 (0.91, 1.64)	0.18
pAurora A nuc	0.93 (0.73,1.20)	0.59	0.92 (0.66, 1.29)	0.63
pAurora A cyt	1.07 (0.83,1.38)	0.60	0.99 (0.78, 1.25)	0.91
PLK1 nuc	0.77 (0.50,1.18)	0.23	0.97 (0.62, 1.54)	0.91
pPLK1 nuc	0.86 (0.60,1.23)	0.41	0.82 (0.55, 1.20)	0.30
FOXM1 nuc	1.03 (0.71,1.48)	0.90	1.02 (0.71, 1.46)	0.92
FOXM1 cyt	1.39 (0.99,1.94)	0.06	1.26 (0.89, 1.77)	0.19
PPP2R1B nuc	0.93 (0.80,1.10)	0.40	0.92 (0.77, 1.10)	0.37
PPP2R1B cyt	0.85 (0.53,1.36)	0.49	0.59 (0.36, 0.96)	0.035
E2F-1 nuc	0.89 (0.71,1.12)	0.32	0.78 (0.58, 1.05)	0.11
p73 nuc	1.02 (0.90,1.14)	0.80	1.00 (0.89, 1.12)	0.97
Cyclin B1 nuc	1.04 (0.63,1.70)	0.89	1.44 (0.82, 2.51)	0.20
Cyclin B1 cyt	0.80 (0.56,1.13)	0.21	0.88 (0.59, 1.32)	0.54
RAD51 cyt	0.91 (0.74,1.11)	0.34	0.87 (0.69, 1.10)	0.25
RAD51 nuc	0.97 (0.69,1.36)	0.87	0.91 (0.63, 1.31)	0.61
BRCA1 nuc	1.48 (1.05,2.09)	0.025	1.08 (0.73, 1.60)	0.72
BRCA1 cyt	1.12 (0.89,1.41)	0.35	0.93 (0.74, 1.17)	0.53
CHK1 nuc	0.67 (0.50,0.90)	0.008	0.57 (0.39, 0.82)	0.002
CHK1 cyt	0.91 (0.66,1.26)	0.57	0.56 (0.36, 0.87)	0.010

PFS progression-free survival, HR hazard ratio per 10 unit increase in each marker, CI confidence interval, Nuc nuclear compartment, Cyt cytoplasmic compartment

^†Stage was categorized as III/IV vs. I/II when included as a covariate in each regression model

^‡P values were derived from the Cox proportional hazards regression model